Cambridge, MA – Convergent Therapeutics has announced the appointment of Andrew Davis as Chief Business and Strategy Officer. About Convergent Therapeutics: Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

For more information visit: https://convergentrx.com/

Convergent Therapeutics
1 Broadway 14th Floor
Cambridge, MA 2142
Phone: 631-215-3897
LinkedIn Page: https://www.linkedin.com/company/convergent-therapeutics/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved